Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JNJ-64232025 in Healthy Participants
NCT03550950Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2018
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-64232025 in autoimmune diseases (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Treatment-Emergent Adverse Events, Number of Participants with Serious Adverse Events and 3 more. Started Jun 2018; status: completed.
02
Drugs
JNJ-64232025
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT03550950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03550950.